This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Shareholder approval of the financial statements for 2013
Dividend of €2.80 per share payable as of May 15, 2014
Board Composition: election of all proposed Directors
PARIS, May 5, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced its Annual General Shareholder Meeting was held today at the Palais des Congrès in Paris. All resolutions were adopted by its shareholders. During the meeting, shareholders approved, among other resolutions, the individual Company and consolidated financial statements for the year 2013. At the General Meeting, shareholders decided the distribution of a cash dividend in the amount of €2.80 per share which will be detached on Euronext Paris on May 12, 2014 with payment as of May 15, 2014.
The General Meeting also elected Patrick Kron as Director and renewed as Directors Christopher Viehbacher, Robert Castaigne and Christian Mulliez, for a term of four years,
i.e., until the General Meeting called to approve the financial statements for the year 2017. Lord Douro, whose term of office has expired, did not express the desire to have his mandate renewed.
After the General Meeting, the new Board of Directors is comprised of 16 members, of whom four are women and eleven are independent Directors. It consists of the following members:
Serge Weinberg*, Chairman of the Board of Directors
Christopher Viehbacher, Chief Executive Officer
Uwe Bicker *
Robert Castaigne *
Jean-René Fourtou *
Claudie Haigneré *
Fabienne Lecorvaisier *
Suet-Fern Lee *
Carole Piwnica *
Klaus Pohle *
Gérard Van Kemmel *
The voting results will be available on the Company's website (
www.sanofi.com ) in the coming days.
The audiocast of the Annual General Shareholder Meeting is available on the Company's website (
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY)